PhD Scientific Days 2017

Oral Presentations: Clinical Sciences

Complement Fixation Test for Diagnosis of Bullous Pemphigoid

Előadó neve

Dr. Horváth N., Orsolya

Előadó munkahelye

Semmelweis University, Dept. of Behavioural Sciences / Ludwig-Maximilian University, Dept. of Dermatology

Előadó telefonszáma

+4917681601978

Előadó e-mail címe

orsolya.horvath@med.uni-muenchen.de

Az előadás címe

Complement Fixation Test for Diagnosis of Bullous Pemphigoid

Szerző(k) neve és munkahelye

Orsolya Horváth N., 1, 2; Jana Jankásková, 1, 3; Rita Varga, 1; Thomas Ruzicka, 1; Miklós Sárdy, 1, 4
1 Department of Dermatology and Allergology, Ludwig-Maximilians University, Munich, Germany
2 Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary
3 Department of Dermato-Venereology, Teaching Hospital Královské Vinohrady, Third Faculty of Medicine, Charles University, Czech Republic
4 Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary

Szekció

Oral Presentations: Clinical Sciences

Data of the presenter

Doctoral School: Mental Health Sciences
Program: Mental Health Sciences and Dermatology
Supervisor: Purebl György, Miklós Sárdy
E-mail address: orsolya.horvath@med.uni-muenchen.de

Text of the abstract

Introduction: The complement fixation test (CFT) is commonly used for diagnosis of gestational pemphigoid, which is immunopathogenetically closely related to bullous pemphigoid (BP), and occurs during pregnancy or shortly thereafter. CFT is a special IIF method performed on healthy human salt-split skin tissue sections detecting complement C3 fixed by IgG. Its performance in diagnosis of BP has not been investigated in a large patient cohort.
Aims: The aim of this study was to analyze the operating characteristics of the CFT.
Method: Single-center, retrospective, serological case-control study of 300 patients with BP and 136 controls.
Results: CFT was found to have a sensitivity of 71.7% and a specificity of 100%. Furthermore, CFT diagnosed 20 of 46 patients with BP (43.5%) who were negative for both BP180 and BP230 enzyme-linked immunoassays (ELISAs), 31 of 66 patients (47.0%) who were negative for indirect immunofluorescence on monkey esophagus, 5 of 14 patients (35.7%) who were serologically negative for all investigated serological assays, and 7 of 18 patients (38.9%) in whom direct immunofluorescence was negative.
Conclusion: Single serological tests usually detect 60–80% of patients with BP. The combination of CFT with all serological assays resulted in a sensitivity of 95.3%. In conclusion, the combination of CFT with other assays increases sensitivity by approximately 10–15%, and has the advantage of an extremely high specificity for BP.
CFT is suitable for the diagnosis of BP, and can help to diagnose serologically challenging cases.

Kind

Szabad

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

1125

Authors (legacy)

Orsolya Horváth N., 1, 2; Jana Jankásková, 1, 3; Rita Varga, 1; Thomas Ruzicka, 1; Miklós Sárdy, 1, 4
1 Department of Dermatology and Allergology, Ludwig-Maximilians University, Munich, Germany
2 Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary
3 Department of Dermato-Venereology, Teaching Hospital Královské Vinohrady, Third Faculty of Medicine, Charles University, Czech Republic
4 Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary